These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 33009446)

  • 1. Characterization of five novel vasopressin V2 receptor mutants causing nephrogenic diabetes insipidus reveals a role of tolvaptan for M272R-V2R mutation.
    Prosperi F; Suzumoto Y; Marzuillo P; Costanzo V; Jelen S; Iervolino A; Guarino S; La Manna A; Miraglia Del Giudice E; Perna AF; Zacchia M; Cordat E; Capasso G; Trepiccione F
    Sci Rep; 2020 Oct; 10(1):16383. PubMed ID: 33009446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
    Takahashi K; Makita N; Manaka K; Hisano M; Akioka Y; Miura K; Takubo N; Iida A; Ueda N; Hashimoto M; Fujita T; Igarashi T; Sekine T; Iiri T
    J Biol Chem; 2012 Jan; 287(3):2099-106. PubMed ID: 22144672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the V2 Vasopressin Receptor (V2R) Mutations Causing Partial Nephrogenic Diabetes Insipidus Highlights a Sustainable Signaling by a Non-peptide V2R Agonist.
    Makita N; Sato T; Yajima-Shoji Y; Sato J; Manaka K; Eda-Hashimoto M; Ootaki M; Matsumoto N; Nangaku M; Iiri T
    J Biol Chem; 2016 Oct; 291(43):22460-22471. PubMed ID: 27601473
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus in a polarized cell model.
    Robben JH; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2005 Aug; 289(2):F265-72. PubMed ID: 16006591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification, characterization and rescue of a novel vasopressin-2 receptor mutation causing nephrogenic diabetes insipidus.
    Ranadive SA; Ersoy B; Favre H; Cheung CC; Rosenthal SM; Miller WL; Vaisse C
    Clin Endocrinol (Oxf); 2009 Sep; 71(3):388-93. PubMed ID: 19170711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Functional rescue of vasopressin V2 receptor mutants in MDCK cells by pharmacochaperones: relevance to therapy of nephrogenic diabetes insipidus.
    Robben JH; Sze M; Knoers NV; Deen PM
    Am J Physiol Renal Physiol; 2007 Jan; 292(1):F253-60. PubMed ID: 16926443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The V2 receptor antagonist tolvaptan raises cytosolic calcium and prevents AQP2 trafficking and function: an in vitro and in vivo assessment.
    Tamma G; Di Mise A; Ranieri M; Geller A; Tamma R; Zallone A; Valenti G
    J Cell Mol Med; 2017 Sep; 21(9):1767-1780. PubMed ID: 28326667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriate polarization following pharmacological rescue of V2 vasopressin receptors encoded by X-linked nephrogenic diabetes insipidus alleles involves a conformation of the receptor that also attains mature glycosylation.
    Tan CM; Nickols HH; Limbird LE
    J Biol Chem; 2003 Sep; 278(37):35678-86. PubMed ID: 12824183
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
    Robben JH; Kortenoeven ML; Sze M; Yae C; Milligan G; Oorschot VM; Klumperman J; Knoers NV; Deen PM
    Proc Natl Acad Sci U S A; 2009 Jul; 106(29):12195-200. PubMed ID: 19587238
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vasopressin-independent targeting of aquaporin-2 by selective E-prostanoid receptor agonists alleviates nephrogenic diabetes insipidus.
    Olesen ET; Rützler MR; Moeller HB; Praetorius HA; Fenton RA
    Proc Natl Acad Sci U S A; 2011 Aug; 108(31):12949-54. PubMed ID: 21768374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. V2R mutations and nephrogenic diabetes insipidus.
    Bichet DG
    Prog Mol Biol Transl Sci; 2009; 89():15-29. PubMed ID: 20374732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered agonist sensitivity of a mutant v2 receptor suggests a novel therapeutic strategy for nephrogenic diabetes insipidus.
    Erdélyi LS; Balla A; Patócs A; Tóth M; Várnai P; Hunyady L
    Mol Endocrinol; 2014 May; 28(5):634-43. PubMed ID: 24628417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetic study of congenital nephrogenic diabetes insipidus and rescue of mutant vasopressin V2 receptor by chemical chaperones.
    Cheong HI; Cho HY; Park HW; Ha IS; Choi Y
    Nephrology (Carlton); 2007 Apr; 12(2):113-7. PubMed ID: 17371330
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AQP2: Mutations Associated with Congenital Nephrogenic Diabetes Insipidus and Regulation by Post-Translational Modifications and Protein-Protein Interactions.
    Gao C; Higgins PJ; Zhang W
    Cells; 2020 Sep; 9(10):. PubMed ID: 32993088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological chaperones in nephrogenic diabetes insipidus: possibilities for clinical application.
    Robben JH; Deen PM
    BioDrugs; 2007; 21(3):157-66. PubMed ID: 17516711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutation in the V2 vasopressin receptor gene, AVPR2, causes nephrogenic syndrome of inappropriate diuresis.
    Erdélyi LS; Mann WA; Morris-Rosendahl DJ; Groß U; Nagel M; Várnai P; Balla A; Hunyady L
    Kidney Int; 2015 Nov; 88(5):1070-8. PubMed ID: 26131744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of three vasopressin receptor 2 variants: an apparent polymorphism (V266A) and two loss-of-function mutations (R181C and M311V).
    Armstrong SP; Seeber RM; Ayoub MA; Feldman BJ; Pfleger KD
    PLoS One; 2013; 8(6):e65885. PubMed ID: 23762448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional characterization of a loss-of-function mutant I324M of arginine vasopressin receptor 2 in X-linked nephrogenic diabetes insipidus.
    Wang L; Guo W; Fang C; Feng W; Huang Y; Zhang X; Liu M; Cui J
    Sci Rep; 2021 May; 11(1):11057. PubMed ID: 34040143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic forms of nephrogenic diabetes insipidus (NDI): Vasopressin receptor defect (X-linked) and aquaporin defect (autosomal recessive and dominant).
    Bichet DG; Bockenhauer D
    Best Pract Res Clin Endocrinol Metab; 2016 Mar; 30(2):263-76. PubMed ID: 27156763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential of nonpeptide (ant)agonists to rescue vasopressin V2 receptor mutants for the treatment of X-linked nephrogenic diabetes insipidus.
    Los EL; Deen PM; Robben JH
    J Neuroendocrinol; 2010 May; 22(5):393-9. PubMed ID: 20163515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.